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D iabetic ketoacidosis (DKA) is a serious complicationof diabetes that occurs primarily in type 1 diabetes
(T1D), although it may also affect patients with other forms
of insulin-dependent diabetes and may occur in new-onset
type 2 diabetes. Insulin deficiency is associated with an in-
crease in glucagon and excessive lipolysis with increased
oxidation of fatty acids to ketone bodies in the liver and
ketonemia. Ketosis may advance to metabolic acidosis. For
DKA to be diagnosed, both ketosis and acidosis must be
present.1–3 If not recognized and/or treated early, it can be-
come serious and life-threatening; 168,000 patients were
admitted to U.S. hospitals for DKA in 2014.4
Recent data from the T1D Exchange, a national registry
including >32,000 U.S. children, adolescents, and adults with
T1D, shed some light on the background risks of DKA. In a
2015 report, <5% of participants reported experiencing DKA,
which occurred most often in children (3%–4%), adolescents
13–17 years of age (4%), and young adults 18–25 years (5%),
but in <2% of older patients. DKA rates generally increased
with inadequate glucose control, occurring most often in
patients with A1C ‡9.0%. Overall, 2.3% of insulin pump
users and 4.3% of those using multiple daily insulin injec-
tions (MDI) reported DKA.5 The T1D Exchange 5-year
follow-up data (2018) are consistent with these findings and
highlight the higher prevalence with increasing A1C values
(presented at T1D Exchange Annual meeting, March 2018,
Tampa Bay, Florida).
That DKA occurs more frequently among patients using
MDI than pumps contrasts with the general consensus that
insulin pump use increases the risk of DKA.6 It is possible
that patients and physicians are reluctant to choose pump
therapy in a patient who is nonadherent to intensive insu-
lin therapy. DKA usually occurs due to deliberate or acci-
dental insulin omission or concurrent infections and other
physiologic stressors (e.g., pancreatitis, trauma, surgery).
Among patients using pumps, the most frequently reported
causes of DKA include missed insulin doses and pump
malfunctions, including insulin delivery interruptions caused
by problems with the infusion set, subcutaneous catheter, or
disconnections.6–8 These problems were common in the first
5–10 years after insulin pumps were introduced and led many
patients and providers to discontinue pump therapy. This
prompted technological advances such as hyperglycemic
alerts and alarms and improved catheters, as well as patient/
provider education and training, which have significantly
reduced DKA risk to the levels seen today. Among MDI
users, newer, longer acting basal insulin analogues with a
longer half-life and duration of action (glargine U100, glar-
gine U300, and degludec U100 or U200) may reduce the risk
of DKA by providing coverage for periods where bolus or
correction doses might be missed or insufficient.9–11
Recent data from studies of selective sodium glucose
cotransporter-2 (SGLT2) inhibitors and a dual SGLT1 and
SGLT2 inhibitor as adjuncts to insulin in T1D demonstrate a
higher incidence of DKA with these agents than with placebo
in some, but not all, studies.12–19 SGLT inhibition increases
the risk of DKA, even as it reduces A1C, glycemic vari-
ability, overall insulin dose, and body weight without in-
creasing severe or total hypoglycemia.14–18,20 Based on the
case reports of DKA in patients with T1D treated with
SGLT2 inhibitors, it is clear that this treatment is being used
in practice, although at a low rate (presented at T1D Ex-
change Annual meeting, March 2018, Tampa Bay, Florida).
As diabetes therapeutic paradigms evolve, clinicians should
be prepared to educate patients and clinic staff about DKA
risks, how best to prevent ketosis from progressing to DKA,
and early treatment of DKA.
Due to their insulin-independent mechanism of action,
SGLT2 or dual SGLT1 and 2 inhibitors lower total daily
insulin dose requirements, which may be expected to increase
ketosis. If ketosis is not treated, it may progress to DKA,
especially in the setting of insulin resistance associated with
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illness or infection. SGLT2 inhibitor-mediated increases in
sodium reabsorption in renal tubules may interfere with renal
clearance of ketone bodies, further increasing circulating
ketones. Volume depletion from SGLT2 inhibition may also be
a factor, as DKA typically is associated with dehydration, and
rehydration is an important component of DKA treatment.1,2
Meanwhile, glucagon levels rise in response to SGLT2 inhi-
bition, possibly to compensate for increased urinary excre-
tion of glucose.21,22 SGLT2 inhibition also augments
preproglucagon gene expression by acting directly on SGLT2
receptors in pancreatic alpha cells.23 The resulting increased
glucagon levels promote additional ketogenesis in the liver.9
DKA in the setting of SGLT inhibition may be associated with
euglycemia (due to significant glycosuria with SGLT2 inhi-
bition in the kidneys), complicating the diagnosis of DKA.
Without the threshold of marked hyperglycemia, DKA diag-
nosis may be delayed or missed by patients and clinicians.
Phase 3 clinical trial programs were recently completed for
the selective SGLT2 inhibitors dapagliflozin (Efficacy and
Safety of Dapagliflozin in Patients with Inadequately Con-
trolled T1D [DEPICT] 1 and 2) and empagliflozin (Empa-
gliflozin as Adjunctive to Insulin in Patients with T1D
Mellitus [EASE] 2 and 3), which are approved for type 2
diabetes, and the investigational dual SGLT1 and 2 inhibitor
sotagliflozin (inTandem1, 2, and 3).14–18,24 The increased
risk of DKA with SGLT2 inhibition may not necessarily
preclude the use of these agents in combination with insulin
therapy, as they have demonstrated significant reductions in
glucose, weight, insulin dose, glycemic variability, and blood
pressure, as well as a decreased incidence of hypoglycemia in
some studies.14–18 While we await regulatory decisions, a re-
examination of DKA management strategies is worthwhile
for the diabetes community. Just as improved clinician and
patient education helped reduce the rate of DKA among in-
sulin pump users, a greater understanding of the prevention,
early detection, and prompt treatment of DKA may reduce
the likelihood of the condition arising or becoming serious,
whether patients are using SGLT inhibitor therapy.
Prevention of ketosis is, ideally, the first step. Patients
should avoid excess alcohol and very-low-carbohydrate or
ketogenic diets (especially if taking an SGLT inhibitor).
Those who participate in extreme athletic activities (e.g.,
marathon running) should do so only in close consultation
with their healthcare team, and ketones should be closely
monitored during metabolically stressful events, including
extreme sports and surgical procedures. SGLT inhibitor
therapy should be temporarily discontinued 24 h in advance
of any planned activity that might precipitate DKA—mainly
situations that result in decreased insulin doses such as sur-
gery, fasting, reduced carbohydrate intake, or prolonged ac-
tivity.25 SGLT inhibitors should also be withheld for illness
and dehydration—any sign or symptoms of physical illness
should prompt testing for ketones. When initiating and
maintaining SGLT therapy in T1D, clinicians should care-
fully monitor insulin dose reductions, especially basal insulin
decreases (pump or MDI). There are differences in insulin
dose reductions with different SGLT inhibitors; for example,
patients on selective SGLT2 inhibitors such as dapagliflozin
or empagliflozin may have larger reductions of basal insulin
than bolus insulin.17,26 In contrast, the dual SGLT1 and 2
inhibitor sotagliflozin has been associated with larger re-
ductions of bolus insulin than basal insulin, because SGLT1
inhibition in the proximal gastrointestinal tract leads to a
blunting and delay of postprandial hyperglycemia and a
lower requirement for bolus insulin.14–16
Early recognition of impending DKA is of paramount
importance. Usual symptoms include nausea, vomiting, and
dehydration associated with excessive thirst and increased
urination, fatigue, loss of appetite, malaise, weakness, and
rapid breathing or shortness of breath. Routine urine or blood
ketone monitoring should be considered, especially during
metabolically stressful situations. Blood ketone levels are
more accurate for assessing degree of ketonemia than urine
ketones.27 Renal reabsorption of ketones may lead to lower
urinary ketone measurements for a given level of ketosis.25
Insulin pump users should check for pump failure or catheter
inclusions or kinking and verify that insulin is being ad-
ministered. When ketosis is present, prompt treatment can
reverse ketosis and prevent progression to DKA. Patients
should consume at least 30–60 grams of carbohydrates and
drink 200–500 mL of fluid. A correction dose of insulin (1.5
times the usual dose) should be taken at the same time as the
carbohydrates and fluids, and additional correction insulin
and carbohydrates should be taken every 1–2 h in the setting
of SGLT-associated ketonemia regardless of whether their
blood glucose is in the euglycemic range. Patients should call
their clinician and recheck ketones every 2–4 h. Finally, the
patient should seek medical attention if any of these steps
cannot be followed, particularly if the patient is unable to
keep down fluids or if ketonemia does not resolve within
4–6 h. Emergency treatment should be sought if symptoms of
DKA occur, including abdominal pain, nausea, vomiting,
fatigue, malaise, and/or dyspnea.
Table 1. STICH Protocol Involving
Administration of Insulin, Carbohydrates,
and Fluids Once Ketosis Has Been Confirmed
in the Setting of SGLT Inhibitor Use in Combination
with Insulin for the Treatment of Type 1 Diabetes
Step 1 Verify ketosis by early symptoms as
described above
Identify conditions that might be
causing ketosisa
Test for ketones
Step 2 STICH protocol




Consume 30 g carbohydrates
+
Hydrate
Step 3 Recheck ketones every 3–4 h
Step 4 Seek emergency medical care if ketosis
does not resolve or if symptoms of
DKA appear, including abdominal pain,
nausea, vomiting, fatigue, and/or dyspnea
aSymptoms may start hours after last SGLT inhibitor dose (e.g., if
SGLT inhibitor is taken in the morning, symptoms may begin in the
evening).
bPatients should not take the SGLT inhibitor after ketosis is
detected and not take another dose until ketones have resolved.
DKA, diabetic ketoacidosis; SGLT, sodium glucose cotransporter.
the patient does not meet a glucose threshold for DKA di-
agnosis, for example:3
 Ketonemia >3.0 mmol/L or significant ketonuria (more
than 2+ on standard urine sticks)
 Blood glucose >200 mg/dL or known diabetes mellitus
 Bicarbonate (HCO3
-) <15.0 mmol/L and/or venous pH
<7.3
It is important to note that blood glucose values may be
<150 mg/dL (so-called euglycemic DKA), and measurements
FIG. 1. Sample wallet card. (A) Front of card. (B) Back of card.
These steps are summarized in Table 1, outlining the 
STICH protocol, a proposed early treatment regimen for 
patients to begin when they detect high ketone levels. Steps 
include stopping SGLT treatment for a few days, insulin 
administration, carbohydrate consumption, and adequate 
hydration with a suitable drink (water or noncaloric athletic 
drink with balanced electrolytes).
DKA associated with SGLT2 inhibitors may present with 
signs and symptoms different from those typically associated 
with DKA.1–3,25 Recent diagnostic criteria can still be used if
of ketonuria and bicarbonate may not accurately reflect pa-
tients’ metabolic state due to the renal action of SGLT in-
hibitors. Direct measurement of b-hydroxybutyrate and pH is
recommended to confirm DKA diagnosis in patients taking
SGLT inhibitors.25 Patients taking SGLT inhibitors should be
advised to carry a wallet card with information about how
DKA presentation may differ from standard DKA (Fig. 1). In
the emergency department, the same protocol involving car-
bohydrates, fluids, and insulin should be used to treat DKA.
If off-label use of SGLT2 inhibitors is being considered
for patients with T1D, it is important for both clinicians and
patients to be aware of conditions that increase the risk
of ketosis, and patients must be willing to check ketones
using recommended guidelines. Whenever ketone levels are
>3.0 mmol/L, the patient should contact the clinician.
DKA is both preventable and manageable. Mitigating the
risks of DKA involves building awareness among clinicians
and patients about precipitating factors and how to avoid or
minimize their impact. Recent innovations in diabetes treat-
ment, including advances in the design of insulin pumps and
use of Continuous Glucose Monitoring (CGM) devices as
well as longer acting basal insulin formulations, may reduce
DKA risk in patients with diabetes treated with intensive,
basal-bolus insulin regimens. Among patients using SGLT
inhibitors with insulin (currently off-label in T1D), additional
education on how and why SGLT2 inhibition may increase
DKA risk—and strategies to appropriately monitor and re-
spond to ketosis—can allow patients with T1D and clinicians
to safely use this new adjunctive therapeutic approach if
approved by regulatory authorities.
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